JP2023539525A - 抗体療法 - Google Patents

抗体療法 Download PDF

Info

Publication number
JP2023539525A
JP2023539525A JP2023514116A JP2023514116A JP2023539525A JP 2023539525 A JP2023539525 A JP 2023539525A JP 2023514116 A JP2023514116 A JP 2023514116A JP 2023514116 A JP2023514116 A JP 2023514116A JP 2023539525 A JP2023539525 A JP 2023539525A
Authority
JP
Japan
Prior art keywords
days
seq
vaccine
weeks
binding agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023514116A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539525A5 (cg-RX-API-DMAC7.html
Inventor
ベノニソン,フライン
ミデルバーグ,ジム
ヴァン・ホール,ソーボールド
アルティンタス,イシル
ケンパー,クリステル
シューマン,ジャニーン
ロイド,ケイティ・アン
オフチンニコフ,ヴィタリス
ゾム,ギスベルトゥス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Original Assignee
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab AS filed Critical Genmab AS
Publication of JP2023539525A publication Critical patent/JP2023539525A/ja
Publication of JP2023539525A5 publication Critical patent/JP2023539525A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2023514116A 2020-09-02 2021-09-02 抗体療法 Pending JP2023539525A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20194018.6 2020-09-02
EP20194018 2020-09-02
PCT/EP2021/074314 WO2022049220A2 (en) 2020-09-02 2021-09-02 Antibody therapy

Publications (2)

Publication Number Publication Date
JP2023539525A true JP2023539525A (ja) 2023-09-14
JP2023539525A5 JP2023539525A5 (cg-RX-API-DMAC7.html) 2024-09-09

Family

ID=72340230

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023514116A Pending JP2023539525A (ja) 2020-09-02 2021-09-02 抗体療法

Country Status (7)

Country Link
US (1) US20230310599A1 (cg-RX-API-DMAC7.html)
EP (1) EP4208200A2 (cg-RX-API-DMAC7.html)
JP (1) JP2023539525A (cg-RX-API-DMAC7.html)
CN (1) CN116472060A (cg-RX-API-DMAC7.html)
BR (1) BR112023003868A2 (cg-RX-API-DMAC7.html)
IL (1) IL300835A (cg-RX-API-DMAC7.html)
WO (1) WO2022049220A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3322727T3 (fi) 2015-07-15 2026-03-17 Genmab As Humanisoituja tai kimeerisiä CD3-vasta-aineita
KR20230008775A (ko) 2020-05-08 2023-01-16 젠맵 에이/에스 Cd3 및 cd20에 대한 이중특이적 항체
US20220313816A1 (en) * 2021-04-01 2022-10-06 Human Vaccines Project Compositions and methods for antibody-as-adjuvant vaccines and therapeutics

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019503363A (ja) * 2015-12-22 2019-02-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 急性リンパ芽球性白血病を治療するための二重特異性の抗cd20/抗cd3抗体
WO2019224718A2 (en) * 2018-05-24 2019-11-28 Janssen Biotech, Inc. Psma binding agents and uses thereof
WO2019241216A1 (en) * 2018-06-14 2019-12-19 Bioatla, Llc Multi-specific antibody constructs
WO2019246356A1 (en) * 2018-06-21 2019-12-26 Regeneron Pharmaceuticals, Inc. Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 1가 항체 및 그의 제조 방법
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US8658178B2 (en) * 2008-03-19 2014-02-25 Yale University Carbon nanotube compositions and methods of use thereof
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス,インコーポレーテッド 共有結合型ダイアボディ及びその使用
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗-vegf/抗-ang-2抗體
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
BR112013002167A2 (pt) 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
WO2014006217A1 (en) * 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
MX428954B (es) * 2013-03-15 2025-11-13 Univ Pennsylvania Vacunación mejorada contra la hormona liberadora de la hormona de crecimiento (ghrh) humana.
CN105073128A (zh) * 2013-04-03 2015-11-18 Ibc药品公司 用于诱导对疾病的免疫应答的组合疗法
KR102813816B1 (ko) 2013-07-05 2025-05-29 젠맵 에이/에스 인간화 또는 키메라 cd3 항체
US9727636B2 (en) 2013-09-30 2017-08-08 Microsoft Technology Licensing, Llc Generating excutable code from complaint and non-compliant controls
SG11201907867TA (en) 2017-02-28 2019-09-27 Bristol Myers Squibb Co Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
KR20190123328A (ko) * 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
AU2019274654B2 (en) * 2018-05-23 2023-07-20 Pfizer Inc. Antibodies specific for CD3 and uses thereof
BR112020023508A2 (pt) * 2018-05-24 2021-03-30 Janssen Biotech, Inc. Anticorpos anti-cd3 e usos dos mesmos
BR112021008486A2 (pt) * 2018-11-01 2021-10-26 Shandong New Time Pharmaceutical Co., Ltd Anticorpo biespecífico e seu uso

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019503363A (ja) * 2015-12-22 2019-02-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 急性リンパ芽球性白血病を治療するための二重特異性の抗cd20/抗cd3抗体
WO2019224718A2 (en) * 2018-05-24 2019-11-28 Janssen Biotech, Inc. Psma binding agents and uses thereof
WO2019241216A1 (en) * 2018-06-14 2019-12-19 Bioatla, Llc Multi-specific antibody constructs
WO2019246356A1 (en) * 2018-06-21 2019-12-26 Regeneron Pharmaceuticals, Inc. Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies

Also Published As

Publication number Publication date
WO2022049220A2 (en) 2022-03-10
CN116472060A (zh) 2023-07-21
US20230310599A1 (en) 2023-10-05
EP4208200A2 (en) 2023-07-12
IL300835A (en) 2023-04-01
WO2022049220A3 (en) 2022-04-21
BR112023003868A2 (pt) 2023-04-04

Similar Documents

Publication Publication Date Title
ES2432357T3 (es) Anticuerpos enteramente humanos contra 4-1BB humano (CD137)
KR102287523B1 (ko) Cd123 및 cd3에 결합할 수 있는 이중특이성 1가 디아바디 및 그것의 용도
US20120121592A1 (en) Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells
WO2012122396A1 (en) Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
CA2878427A1 (en) Multimeric fusion protein vaccine and immunotherapeutic
CA2807585A1 (en) Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
KR20090127886A (ko) 수지상 세포 렉틴 유사 산화된 ldl 수용체-1(lox-1)을 통한 사람 항원제시세포의 활성화
US20230310599A1 (en) Antibody therapy
CN102884194B (zh) 含增强免疫应答的Fc融合蛋白的方法和组合物
US20240336667A1 (en) Method of treating diseases with anti-pd-l1/il-10 fusion proteins
JP2024538141A (ja) 活性化可能なポリペプチド複合体
JP7729561B2 (ja) 多発性骨髄腫治療用の抗bcma car t細胞
JP2013520482A (ja) 癌ワクチン
Schaedler et al. Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors
JP2023539525A5 (cg-RX-API-DMAC7.html)
CN109929037A (zh) 针对程序性死亡配体的结合物及其应用
TW202207975A (zh) 使用經修飾之pbmc及免疫結合體之組合療法
KR20220137689A (ko) 항원 백신접종 및 pd-l1 및 cd137에 결합하는 결합제를 수반하는 치료
US11185583B2 (en) Multi-functional mucosal vaccine platform
WO2024238558A1 (en) Use of immunomodulating targeted polynucleotide conjugates for use with immune honing agent
CN120302979A (zh) 针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗
AU2022387805A1 (en) Tlr7 agonist and combinations for cancer treatment
CN120456923A (zh) 使用抗il-2抗体的方法
CA3164027A1 (en) Bcg car constructs and methods of their manufacture and use
CN118103406A (zh) 可激活多肽复合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260804